Raymond James & Associates’s Ingevity NGVT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-46,519
| Closed | -$2.21M | – | 3906 |
|
|
2023
Q3 | $2.21M | Buy |
46,519
+516
| +1% | +$28.2K | ﹤0.01% | 1961 |
|
|
2023
Q2 | $2.68M | Buy |
46,003
+280
| +0.6% | +$16.8K | ﹤0.01% | 1880 |
|
|
2023
Q1 | $3.27M | Buy |
45,723
+1,198
| +3% | +$95.1K | ﹤0.01% | 1752 |
|
|
2022
Q4 | $3.14M | Sell |
44,525
-103
| -0.2% | -$7.26K | ﹤0.01% | 1723 |
|
|
2022
Q3 | $2.71M | Buy |
44,628
+1,026
| +2% | +$68.8K | ﹤0.01% | 1772 |
|
|
2022
Q2 | $2.75M | Buy |
43,602
+1,949
| +5% | +$127K | ﹤0.01% | 1799 |
|
|
2022
Q1 | $2.67M | Buy |
41,653
+1,425
| +4% | +$95.3K | ﹤0.01% | 1930 |
|
|
2021
Q4 | $2.88M | Buy |
40,228
+5,648
| +16% | +$430K | ﹤0.01% | 1912 |
|
|
2021
Q3 | $2.47M | Sell |
34,580
-779
| -2% | -$61.4K | ﹤0.01% | 1952 |
|
|
2021
Q2 | $2.88M | Buy |
35,359
+602
| +2% | +$48.4K | ﹤0.01% | 1852 |
|
|
2021
Q1 | $2.63M | Sell |
34,757
-1,175
| -3% | -$85.5K | ﹤0.01% | 1836 |
|
|
2020
Q4 | $2.72M | Sell |
35,932
-67,294
| -65% | -$4.38M | ﹤0.01% | 1707 |
|
|
2020
Q3 | $5.1M | Sell |
103,226
-2,814
| -3% | -$159K | 0.01% | 1212 |
|
|
2020
Q2 | $5.58M | Buy |
106,040
+35,192
| +50% | +$1.67M | 0.01% | 1118 |
|
|
2020
Q1 | $2.49M | Buy |
70,848
+29,068
| +70% | +$1.7M | ﹤0.01% | 1447 |
|
|
2019
Q4 | $3.65M | Sell |
41,780
-784
| -2% | -$68.6K | ﹤0.01% | 1460 |
|
|
2019
Q3 | $3.61M | Buy |
42,564
+10,001
| +31% | +$891K | 0.01% | 1419 |
|
|
2019
Q2 | $3.42M | Buy |
32,563
+887
| +3% | +$89.1K | ﹤0.01% | 1464 |
|
|
2019
Q1 | $3.35M | Sell |
31,676
-280
| -0.9% | -$28.1K | 0.01% | 1435 |
|
|
2018
Q4 | $2.67M | Sell |
31,956
-2,932
| -8% | -$265K | ﹤0.01% | 1468 |
|
|
2018
Q3 | $3.55M | Buy |
34,888
+1,424
| +4% | +$137K | 0.01% | 1434 |
|
|
2018
Q2 | $2.71M | Buy |
33,464
+242
| +0.7% | +$19.2K | ﹤0.01% | 1570 |
|
|
2018
Q1 | $2.45M | Buy |
33,222
+106
| +0.3% | +$7.93K | ﹤0.01% | 1583 |
|
|
2017
Q4 | $2.33M | Buy |
33,116
+683
| +2% | +$49.3K | ﹤0.01% | 1592 |
|
|
2017
Q3 | $2.03M | Buy |
32,433
+6
| +0% | +$355 | ﹤0.01% | 1640 |
|
|
2017
Q2 | $1.86M | Buy |
32,427
+9,693
| +43% | +$570K | ﹤0.01% | 1615 |
|
|
2017
Q1 | $1.38M | Sell |
22,734
-135
| -0.6% | -$7.64K | ﹤0.01% | 1780 |
|
|
2016
Q4 | $1.25M | Buy |
22,869
+15,567
| +213% | +$747K | ﹤0.01% | 1804 |
|
|
2016
Q3 | $337K | Sell |
7,302
-24,507
| -77% | -$1.03M | ﹤0.01% | 2543 |
|
|
2016
Q2 | $1.08M | Buy |
+31,809
| New | +$993K | ﹤0.01% | 1699 |
|
Other funds holding NGVT
ICP
Raymond James & Associates's NGVT Position: Q4 2023 in Review
Raymond James & Associates sold out of Ingevity (NGVT) in Q4 2023, closing a stake of 46,519 shares — an estimated $2.21M sold.
Raymond James & Associates first reported a position in NGVT in Q2 2016 and held it in 30 quarters. The position peaked at $5.58M in Q2 2020. 252 funds tracked by Wall St. Rank hold NGVT as of Q4 2023.
- Raymond James & Associates reported no remaining Ingevity position as of Q4 2023 after selling out during the quarter.
- Raymond James & Associates sold 46,519 Ingevity shares in Q4 2023, an estimated $2.21M.
- Raymond James & Associates first reported a position in Ingevity in Q2 2016 and held it in 30 quarters.
- Raymond James & Associates's Ingevity position peaked at $5.58M in Q2 2020.
- 252 funds tracked by Wall St. Rank held Ingevity as of Q4 2023.
Based on Raymond James & Associates's 13F filing for Q4 2023, filed 16 Jan 2024.